Watch out for these 3 mid-cap stocks that doubled investors' wealth in 2021, so far! Watch out for these 3 mid-cap stocks that doubled investors' wealth in 2021, so far! Outperformance of mid-cap stocks when compared with domestic benchmark indices has surely created a bullish sentiment among investors for including them in their portfolios. DSIJ Intelligence / Tuesday, July 27, 2021 / Article rating: 3.6 In 2021, so far, BSE Midcap index has outperformed the domestic benchmark indices by gaining around 25.9 per cent. Meanwhile, Sensex and Nifty have gained 9.82 per cent & 12.31 per cent, respectively.
In conversation with Nitin Kabadi, Head-ETF Business, ICICI Prudential AMC In conversation with Nitin Kabadi, Head-ETF Business, ICICI Prudential AMC DSIJ Intelligence / Tuesday, July 27, 2021 / Article rating: 4.0 When investing in the ETF form, an investor has the flexibility to buy & sell the investment on the stock exchanges just like transacting a stock and in addition, he also gets access to all the benefits of investing.
Sharp crack in Asian counterparts send shiver down the spine of investors on D-Street Sharp crack in Asian counterparts send shiver down the spine of investors on D-Street DSIJ Intelligence-3 / Tuesday, July 27, 2021 / Article rating: 3.5 Among Asian peers, Hong Kong’s Hang Seng is down by more than 4 per cent while China’s Shanghai Composite too witnessed losses of nearly 2.5 per cent.
RTAs to develop integrated mutual funds transaction platform for investors RTAs to develop integrated mutual funds transaction platform for investors DSIJ Intelligence / Tuesday, July 27, 2021 / Article rating: 5.0 The circular by SEBI has also specified that AMCs & depositories shall facilitate and RTAs shall make the aforesaid platform operational in a phased manner.
Ten stocks close to their 52-week high Ten stocks close to their 52-week high DSIJ Intelligence / Tuesday, July 27, 2021 / Article rating: 3.6 The market opened in green on July 27, 2021.
Five stocks witnessing long built-up Five stocks witnessing long built-up DSIJ Intelligence / Tuesday, July 27, 2021 / Article rating: 4.0 The market opened in green on July 27, 2021, overall volumes in futures & options currently stand at 4,28,58,792 contracts with a turnover of Rs. 36,04,114.35 crore.
Five stocks witnessing short built-up Five stocks witnessing short built-up DSIJ Intelligence / Tuesday, July 27, 2021 / Article rating: 2.9 The market opened in green on July 27, 2021, overall volumes in futures & options currently stand at 4,28,58,792 contracts with a turnover of Rs. 36,04,114.35 crore.
KPIT Technologies reports strong performance in Q1FY22; share gains on Tuesday KPIT Technologies reports strong performance in Q1FY22; share gains on Tuesday The stock has delighted investors by delivering gains of 347.35 per cent in the last one year & 108.03 per cent in 2021, so far. DSIJ Intelligence / Tuesday, July 27, 2021 / Article rating: 3.4 KPIT Technologies, an Indian multinational corporation, announced its quarterly results for Q1FY22. During the year, the company has also entered T25 engagements across geographies.
Jindal Stainless rallies 5 per cent on posting strong Q1 results; announces Rs 2,150 crore expansion plan Jindal Stainless rallies 5 per cent on posting strong Q1 results; announces Rs 2,150 crore expansion plan The estimated Capex of this brownfield expansion is Rs 2,150 crore. The three-pronged expansion plan envelopes the expansion of melting capacity and commensurate strengthening of forward as well as backward linkages. DSIJ Intelligence / Tuesday, July 27, 2021 / Article rating: 3.0 The company accelerated its deleveraging strategy during the quarter and narrowed long-term external debt (excluding group company JSHL’s debt) by Rs 210 crore.
Biocon Biologics partners with Adagio Therapeutics to advance antibody for COVID-19 prevention & treatment Biocon Biologics partners with Adagio Therapeutics to advance antibody for COVID-19 prevention & treatment ADG20 is a novel monoclonal antibody, targeting the spike protein of related Coronaviruses and SARS-CoV-2. It is currently in global clinical development by Adagio as a single agent for both prevention and treatment of Coronavirus. DSIJ Intelligence / Tuesday, July 27, 2021 / Article rating: 4.0 The fully-integrated biosimilars company, Biocon Biologics Ltd, a subsidiary of Biocon Ltd reported that US-based Adagio Therapeutics has granted them an exclusive licence to manufacture and commercialise, broadly neutralising antibody treatment based on ADG20 for India as well as select emerging markets.